Kuros Biosciences has fully launched the MagnetOs MIS Delivery System, a solution the company claims meets all surgeons’ bone graft delivery needs. Purpose-built for minimally invasive surgical (MIS) procedures, the system was showcased late last week at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Meeting in Las Vegas.

“The launch of MagnetOs MIS is more than a product milestone; it reflects our vision to redefine what’s possible in spine surgery,” Kuros Biosciences CEO Chris Fair said. “By combining efficiency, precision, and the strength of Level I clinical evidence, we’re setting a new standard for minimally invasive care. At Kuros, our mission is to empower surgeons with innovations that don’t just keep pace with the future of surgery but help shape it.”

MagnetOs MIS is being marketed as the only bone graft delivery system that is sterile, prefilled, free of human tissue, and with a mechanism of action backed by Level I clinical evidence.^1,2 MagnetOs MIS meets all critical needs for minimally invasive bone grafting:

• Always ready: Single-use, sterile, and prefilled, available off the shelf with no refrigeration or thawing required¹
• Faster efficiency: Graft placement three times faster than traditional funnel-based delivery methods³
• Engineered for optimal handling: Enabling easy, controlled, and precise graft placement in hard-to-reach spaces

Built on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology to harness the immune system to stimulate bone formation, the MIS system is designed to maximize speed and efficiency in the operating room.^4-6

The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions (TLIF), where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery.⁷ These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%).²

“Kuros Biosciences has delivered an elegant solution that makes MIS graft placement efficient and reliable, without compromise. I was impressed with how seamlessly the system performed and the confidence it provided in delivering MagnetOs precisely into confined spaces,” stated Dr. Matthew Maserati, a neurosurgeon at WellSpan Neurosurgery in Chambersburg, Pa.

Growing bone with MagnetOs gives surgeons confidence by delivering predictable fusion outcomes.²  Among active smokers—who comprised one in five patients—the fusion difference between MagnetOs and autograft was dramatic.^*†2,8 MagnetOs grows bone on its own due to NeedleGrip, a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth without added cells or growth factors.^‡§4-6 Ready-to-use, easy to mold, and reliably staying put, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and cleared by the U.S. Food and Drug Administration (FDA) for use throughout the spine, including interbody procedures.^¶1,9-13

Kuros Biosciences discovers, develops, and delivers biologic technologies. With locations in the United States, Switzerland, and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs, has been used on five continents.

* 19 of initial 100 patients were active smokers.
† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.2
‡ Results from in-vitro or in-vivo laboratory testing may not be predictive of clinical experience in humans.
§ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA and mixed with autograft in posterolateral spine and intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space.

References
¹ Instructions for Use (IFU) MagnetOs MIS (US).
² Stempels, et al. Spine. 2024;49(19):1323-1331.
³ Data on file. MagnetOs MIS.
⁴ Van Dijk, et al. eCM. 2021;41:756-73.
⁵ Van Dijk, et al. J Immunol Regen Med. 2023;19:100070.
⁶ Duan, et al. eCM. 2019;37:60-73.
⁷ Davis, J. et al. Orthopedic Review. 2025.
⁸ Van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024.
⁹ Data on file. MagnetOs Putty and MagnetOs Easypack Putty.
¹⁰ Instructions for Use (IFU) MagnetOs Granules (US).
¹¹ Instructions for Use (IFU) MagnetOs Putty (US).
¹² Instructions for Use (IFU) MagnetOs Easypack Putty (US).
¹³ Instructions for Use (IFU) MagnetOs Flex Matrix (US).